We also built a vaccine manufacturing facility in Maryland that was run by Emergent BioSolutions, and another one located in North Carolina that used a cell-based manufacturing process to make flu vaccine.43 These and other capabilities were constructed as a hedge against a pandemic strain of bird flu, to give us the capacities we would need to manufacture a new vaccine. All of these efforts ran into separate challenges.
